 |
|
|
Proxibarbital
|
|
| Systematic (IUPAC) name | |
| 5-allyl-5-(2-hydroxypropyl)pyrimidine-2,4,6(1H,3H,5H)-trione | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | C10H14N2O4 |
| Mol. mass | 226.229 g/mol |
| Synonyms | Proxibarbital, Centralgol, Ipronal, 5-Allyl-5-(β-hydroxypropyl)barbituric acid |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Proxibarbital (Ipronal) is a barbiturate derivative invented in the 1970s. It has sedative, hypnotic and anticonvulsant properties, and was used in the treatment of migraine headaches in a similar manner to butalbital.[1]
References
- ^ Sulman FG, Pfeifer Y, Tal E. Migraine therapy by enzyme induction with proxibarbital (German). Therapie die Gegenwart. 1976 Dec;115(12):2088-103.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
